Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 110

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 110
---
 natural or man-made disasters or business
interruptions. In addition, we partially rely on our research institution collaborators for conducting research and development of our
drug candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions
could seriously harm our operations and financial condition and increase our costs and expenses. We rely on contract manufacturers to
produce and process our drug candidates. Our ability to obtain clinical supplies of our drug candidates could be disrupted if the operations
of these suppliers are affected by a man-made or natural disaster or other business interruption. A large portion of our contract manufacturer’s
operations is in a single facility. Damage or extended periods of interruption to our corporate or our contract manufacturer’s development
or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could cause
us to cease or delay development of some or all of our drug candidates.

We may be exposed to various risks related to the regulatory environment of the pharmaceutical industry in the PRC.

We are the exclusive licensee
to certain PRC patents directed to our drug candidates; and we also intend to file application for certain products in the PRC. The
pharmaceutical industry in the PRC is subject to comprehensive government regulation and supervision, encompassing the approval, registration,
manufacturing, packaging, licensing and marketing of new drugs. (See “Regulations”). In recent years, the regulatory
framework in the PRC regarding the pharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo
significant changes. Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent
the successful development or commercialization of our drug candidates in the PRC and reduce the current benefits that we believe are
available to us from developing and manufacturing drugs in the PRC. Chinese authorities have become increasingly vigilant in enforcing
laws in the pharmaceutical industry and any failure by us or our partners to maintain compliance with applicable laws and regulations
or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities in the PRC. We
believe our strategy and approach is aligned with the PRC government’s policies, but we cannot ensure that our strategy and approach
will continue to be aligned.

Changes in the political and
economic policies of the PRC government may materially and adversely affect our business, financial condition and results of operations
and may result in our inability to sustain our growth and expansion strategies. Our